Upper tract urothelial carcinoma (UTUC) is a malignancy arising from the urothelial cells lining the urinary tract, including the renal calyces, pelvis, and urethra. This disease is associated with high mortality and a significant burden on the healthcare system. UTUC often accompanies bladder carcinoma, requiring close monitoring of patients for concomitant cancers. The main clinical manifestations include macrohematuria, flank pain, and obstructive urinary symptoms. Importantly, early detection and diagnosis of UTUC are critical to achieving positive treatment outcomes.
History of the disease and interesting historical facts
The history of the study of urothelial carcinoma of the upper urinary tract dates back to the early 20th century. The first cases of this pathology were documented in scientific papers beginning in 1912, when doctors noted a link between smoking and urinary tract cancer. In the 1970s, American oncologist Allan R. Withers conducted a significant study confirming that UTUC was in fact part of a broad group of tumors associated with damage to urothelial cells. The discovery of various mutations in genes such as TP53 and FGFR in the following decades gave rise to new approaches to the treatment and classification of this disease.
Epidemiology
According to various epidemiological studies, the prevalence of urothelial carcinoma varies depending on the geographic region and risk factors. On average, the incidence of UTUC is about 1-2 cases per 100,000 population per year. An increased risk of developing this disease is observed in men, in whom the incidence rate is 2-3 times higher than in women. It is known that age also plays a significant role: the greatest number of cases are registered in patients over 50 years of age. In recent years, there has been a tendency towards an increase in the incidence, which is associated with an increase in risk factors, including smoking and exposure to certain chemicals.
Genetic predisposition to this disease
Genetic predisposition to urothelial carcinoma of the upper urinary tract is achieved through various mutations and polymorphisms in certain genes. The main genes involved in the development of UTUC are TP53, FGFR3, RAS and the gene of classic hereditary cancer - TSC1. Mutations in TP53 are often associated with a poor prognosis due to increased tumor aggressiveness. Studies have shown that hereditary factors can play a significant role in the development of the disease, so an analysis of family history and identification of concomitant diseases in relatives is carried out.
Risk factors for the development of this disease
Risk factors for the development of urothelial carcinoma of the upper urinary tract can be divided into several categories:
- Physical factors: long-term exposure to carcinogenic substances such as aniline dyes and environments contaminated with heavy metals.
- Chemical factors: tobacco smoking, which increases the risk of UTUC by 2-6 times compared to non-smokers.
- Medical history: history of bladder cancer, previous urinary tract surgery such as bladder resection, and history of chronic urinary tract infections.
- Professional risks: work in the dye, rubber, chemical and petrochemical industries.
- Other: genetic factors and the presence of comorbidities such as diabetes and hypertension.
Diagnosis of this disease
Diagnosis of urothelial carcinoma of the upper urinary tract includes several stages:
- Main symptoms: macrohematuria, lumbar pain, obstructive symptoms such as urinary retention.
- Laboratory tests: complete urinalysis and urine cytology to detect atypical cells, as well as biochemical parameters of kidney function.
- Radiological examinations: CT of the urinary tract with contrast is the gold standard in UTUC imaging, allowing tumor detection and disease staging.
- Other diagnostic tests include ultrasound, MRI in specific cases, and cystoscopy to visualize the bladder and possible associated cancer.
- Differential diagnosis: diseases such as sarcoidosis, pyelonephritis or benign tumors of the urinary tract must be excluded.
Treatment
Treatment of urothelial carcinoma of the upper urinary tract depends on the stage of the disease and the general condition of the patient:
- General treatment: includes surgical resection of the tumor and/or urinary tract, as well as assessment of the need for adjuvant therapy.
- Pharmacological treatment: used in late stages when the tumor has metastasized, including the use of modern targeted drugs and immunotherapy.
- Surgical treatment: may include both organ-preserving methods and radical nephrectomy.
- Other treatments: Newer techniques such as photodynamic therapy and the use of nanosurgery are being actively researched and clinically applied.
List of medications used to treat this disease
The main groups of drugs used in the treatment of UTUC include:
- Immunotherapeutic agents: Nivolumab, Pembrolizumab.
- Targeted drugs: Erdafitinib and other FGFR inhibitors.
- Chemotherapeutic agents: Cisplatin, Gemcitabine.
- Combination treatment regimens: the use of chemotherapy in combination with immunotherapy.
Disease monitoring
Patients with UTUC are monitored through regular follow-up examinations, including:
- Periodic CT or ultrasound to assess for recurrence.
- Laboratory diagnostic tests to detect atypical cells in urine.
- Clinical assessment of the sacrum and renal function.
The prognosis depends on the stage of the disease and the time of its diagnosis. Complications may include metastasis, uremia, and the need for subsequent surgical interventions.
Age-related features of the disease
Urothelial carcinoma of the upper urinary tract has its own characteristics depending on the age group:
- In elderly patients, the disease often progresses more aggressively due to concomitant pathologies and a general decrease in immune protection.
- Younger patients (under 50 years of age) may have a better prognosis, but they are more likely to be affected by genetic factors.
- In middle age (50-70 years) the incidence rate is highest, which is associated with professional factors and general habits.
Questions and Answers
- What are the main symptoms of urothelial carcinoma of the upper urinary tract? The main symptoms are macrohematuria, low back pain, urinary tract obstruction and potentially infection.
- Who is at high risk for UTUC? Increased risk is seen in smokers, chemical industry workers, and patients with previous bladder disease.
- How is UTUC diagnosed? Typically, CT scan of the urinary tract, laboratory tests, and cystoscopy are used to confirm the diagnosis.
- What treatment is used for this disease? Treatment includes surgery, chemotherapy and immunotherapy, depending on the stage of the disease.
- What is the prognosis for patients with UTUC? The prognosis depends on the stage of the disease, but overall survival is significantly improved with early diagnosis.
